ICML 2021 - 16th International Conference on Malignant Lymphoma (Virtual Meeting)
Jun 18 - Jun 22, 2021 | LuganoSwitzerland
LARVOL is not affiliated with 16th International Conference on Malignant Lymphoma (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 160 abstracts linked to Trials
[VIRTUAL] Genetic Subtype Guided Rituximab-based Immunochemotherapy Improves Outcome in Newly Diagnosed Diffuse Large B-cell Lymphoma: First Report of a Randomized Phase 2 Study
[VIRTUAL] The Combination of Duvelisib and Romidepsin (DR) Is Highly Active Against Relapsed/Refractory Peripheral T-cell Lymphoma with Low Rates of Transaminitis:Final Results
[VIRTUAL] Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Final Results From a Phase 2 Study
[VIRTUAL] High risk follicular lymphoma: treatment options
[VIRTUAL] Brentuximab vedotin as consolidation treatment in patients with stage I/II classical Hodgkin’s lymphoma and a positive FDG-PET after 2 cycles of ABVD: a LYSA phase 2 study.
[VIRTUAL] Camidanlumab Tesirine Efficacy and Safety in an Open-label, Multicenter, Phase 2 Study of Patients (pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
[VIRTUAL] Multi-center phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL)
[VIRTUAL] Nivolumab for relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous transplantation: 5-year overall survival from the phase 2 CheckMate 205 study
[VIRTUAL] TRANSCEND CLL 004: Phase 1 cohort of Lisocabtagene Maraleucel (liso-cel) combined with Ibrutinib (ibr) for patients (pts) with R/R CLL/SLL
[VIRTUAL] A NEW OPTION IN PAIN PREVENTION WITH BLISS©, A DIGITAL THERAPEUTIC SOLUTION LEVERAGING VIRTUAL REALITY: RESULTS OF A FRENCH OPEN-LABEL MULTICENTER RANDOMIZED PHASE III STUDY (REVEH TRIAL)
[VIRTUAL] Bendamustine, followed by Obinutuzumab, Acalabrutinib and Venetoclax in patients (pts) with relapsed/refractory chronic lymphocytic leukemia (CLL): CLL2-BAAG trial of the GCLLSG
[VIRTUAL] CAPTIVATE primary analysis of first-line treatment with fixed-duration ibrutinib plus venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
[VIRTUAL] Early Positron Emission Tomography Response-Adapted Treatment in Localized Diffuse Large B-Cell Lymphoma (aaIPI=0): Results of the Phase 3 LYSA LNH 09-1B Trial.
[VIRTUAL] Efficacy and Safety of Tisagenlecleucel (Tisa-cel) in Adult Patients (Pts) With Relapsed/Refractory Follicular Lymphoma (r/r FL): Primary Analysis of the Phase 2 ELARA Trial
[VIRTUAL] ESA versus MESA with sandwiched radiotherapy in patients with early-stage natural killer/T-cell lymphoma: a multicentre, randomised, phase 3, non-inferiority trial